University Of Washington AIDS Clinical Trial Unit: AIDS Ribbon University Of Washington AIDS Clinical Trial Unit Header
UW AIDS Clinical Trial Unit Home Page UW AIDS Clinical Trial Unit Studies UW AIDS Clinical Trial Unit Staff UW AIDS Clinical Trial Unit Links
UW AIDS Clinical Trial Unit Positivemente Latino UW AIDS Clinical Trial Unit Outreach Page UW AIDS Clinical Trial Unit Contact Us Page
University of Washington Seal
5294 FACT SHEET
A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects Boceprevir, Interferon, Ribavirin to Treat HCV/HIV Coinfected Subjects (BIRTH) (ACTG 5294)
Purpose of This Trial:
To assess if adding Boceprevir (BOC) to the current standard-of-care regimen (Pegylated-interferon alfa 2b [PEG-IFN] + weight-based ribavirin [RBV]) will improve outcomes of hepatitis C virus (HCV) treatment in persons with HCV genotype 1 and HIV co-infection.

You may be eligible if you are:
  • Men or women ≥ 18 years of age with HIV and hepatitis C
  • Have hepatitis C genotype 1 infection
  • Have a hepatitis C viral load greater than 10,000
  • Have had a liver biopsy within 104 weeks prior to entry
  • If on HIV meds, must be taking either raltegravir OR efavirenz AND have undetectable viral load
  • If not on HIV meds, have HIV viral load less than 50,000
  • Have a T-cell count greater than 200
  • Not pregnant or breast feeding or planning pregnancy, or if you are a male, do not have a female partner who is pregnant
  • Cannot be taking a HIV protease inhibitor
Medications While On Study:
Boceprevir, Pegylated-interferon alpha 2b, and Ribavirin (all provided by study)
Length of Study:
72 weeks
Schedule of Study Appointments:
Screening, entry, and weeks 2,4,6,8,10,12,16, 20, 24, and every 4-8 weeks until week 72.
Pharmacokinetic Substudy:
You may be asked to take part in an optional sub-study (A5309s) that looks at the levels of BOC and raltegravir OR efavirenz in your blood. This will require additional blood draws over 12-24 hours on weeks 2 and 6 of the main study.
Reimbursement:
  • Clinical exams, study medications, and lab tests are provided at no cost.
  • You will receive $20 per visit starting at Entry.
  • You will receive $120 for each 12 hour sub-study visits, and another $30 if you have to come back the next day.
Contact:
The ACTU Screening Nurse at 206-744-3184.
return to top of page

Home Research Staff Links Latino Outreach Contact Site Map

© University of Washington AIDS Clinical Trial Unit, updated 08/09/2012.